A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Tsou, Shang Hsun ^a   Chen, Tzer Ming ^a   Hsiao, Hui Ting ^a   Chen, Yen Hui ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN; PROTEIN P53; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL PROLIFERATION; CODON; CONCENTRATION RESPONSE; DNA REPAIR; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GST PI GENE; HUMAN; HUMAN CELL; IC50; MDR GENE; MRP 1 GENE; MULTIDRUG RESISTANCE; NRF 2 GENE; PHENOTYPE; PKC ALPHA GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; BREAST TUMOR; CELL SHAPE; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR GENE;

APOPTOSIS; BREAST NEOPLASMS; CELL SHAPE; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84961291093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116747     Document Type: Article

References (56)

1. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58. doi: 10.1038/nrc706 PMID: 11902585
2. Lim B, Cream LV, Harvey HA (2013) Update on clinical trials: genetic targets in breast cancer. Adv Exp Med Biol 779: 35-54. doi: 10.1007/978-1-4614-6176-0-2 PMID: 23288634
3. Luqmani YA (2005) Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14 Suppl 1: 35-48. doi: 10.1159/000086183 PMID: 16103712
4. Saxena M, Stephens MA, Pathak H, Rangarajan A (2011) Transcription factors that mediate epithelialmesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2: e179. doi: 10.1038/cddis.2011.61 PMID: 21734725
5. O 'Connor R (2007) The pharmacology of cancer resistance. Anticancer Res 27: 1267-1272. PMID: 17593618
6. Munoz M, Henderson M, Haber M, Norris M (2007) Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 59: 752-757. doi: 10.1080/15216540701736285 PMID: 18085475
7. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, et al. (2010) Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 102: 1637-1652. doi: 10.1093/jnci/djq361 PMID: 20935265
8. Ogretmen B, Safa AR (1997) Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 14: 499-506. doi: 10.1038/sj.onc.1200855 PMID: 9053847
9. Mehta K, Devarajan E, Chen J, Multani A, Pathak S (2002) Multidrug-resistant MCF-7 cells: an identity crisis? J Natl Cancer Inst 94: 1652-1654; author reply 1654. doi: 10.1093/jnci/94.21.1652-b PMID: 12419794
10. Rusetskaya NV, Lukyanova NY, Chekhun VF (2009) Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin. Exp Oncol 31: 140-143. PMID: 19783968
11. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162. doi: 10.1016/0005-2736(76)90160-7 PMID: 990323
12. Stavrovskaya AA, Stromskaya TP (2008) Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc) 73: 592-604. doi: 10.1134/S0006297908050118
13. Scotto KW (2003) Transcriptional regulation of ABC drug transporters. Oncogene 22: 7496-7511. doi: 10.1038/sj.onc.1206950 PMID: 14576854
14. Walsh AC, Feulner JA, Reilly A (2001) Evidence for functionally significant polymorphism of human glutamate cysteine ligase catalytic subunit: association with glutathione levels and drug resistance in the National Cancer Institute tumor cell line panel. Toxicol Sci 61: 218-223. doi: 10.1093/toxsci/61.2.218 PMID: 11353130
15. Schuliga M, Chouchane S, Snow ET (2002) Upregulation of glutathione-related genes and enzyme activities in cultured human cells by sublethal concentrations of inorganic arsenic. Toxicol Sci 70: 183-192. doi: 10.1093/toxsci/70.2.183 PMID: 12441363
16. Ryter SW, Otterbein LE, Morse D, Choi AM (2002) Heme oxygenase/carbon monoxide signaling pathways: regulation and functional significance. Mol Cell Biochem 234-235: 249-263. doi: 10.1023/ A:1015957026924 PMID: 12162441
17. Dhillon KK, Swisher EM, Taniguchi T (2011) Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 102: 663-669. doi: 10.1111/j.1349-7006.2010.01840.x PMID: 21205087
18. Balcer-Kubiczek EK, Yin J, Lin K, Harrison GH, Abraham JM, et al. (1995) p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons. Radiat Res 142: 256-262. doi: 10.2307/3579133 PMID: 7761574
19. Caamano J, Ruggeri BA, Klein-Szanto AJ (1992) A catalog of p53 alterations in selected human and laboratory animal neoplasms. Prog Clin Biol Res 376: 331-355. PMID: 1528927
20. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, et al. (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276: 39359-39367. doi: 10.1074/jbc. M103429200 PMID: 11483599
21. Gudjonsson T, Magnusson MK (2005) Stem cell biology and the cellular pathways of carcinogenesis. APMIS 113: 922-929. doi: 10.1111/j.1600-0463.2005.apm-371.x PMID: 16480458
22. Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene 23: 7274-7282. doi: 10.1038/sj.onc.1207947 PMID: 15378087
23. O 'Flaherty JD, Barr M, Fennell D, Richard D, Reynolds J, et al. (2012) The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy. J Thorac Oncol 7: 1880-1890. doi: 10.1097/JTO.0b013e31826bfbc6 PMID: 23154562
24. Li XX, Wang J, Wang HL, Wang W, Yin XB, et al. (2012) Characterization of cancer stem-like cells derived from a side population of a human gallbladder carcinoma cell line, SGC-996. Biochem Biophys Res Commun 419: 728-734. doi: 10.1016/j.bbrc.2012.02.090 PMID: 22387537
25. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988. doi: 10.1073/pnas. 0530291100 PMID: 12629218
26. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888. doi: 10.1371/journal.pone. 0002888 PMID: 18682804
27. Lin X, Zhang X, Wang Q, Li J, Zhang P, et al. (2012) Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-kappaB signaling pathway in a human breast cancer cell line. Neoplasma 59: 248-256. doi: 10.4149/neo-2012-032 PMID: 22329846
28. Zhao LJ, Xu H, Qu JW, ZhaoWZ, Zhao YB, et al. (2012)Modulation of drug resistance in ovarian cancer cells by inhibition of protein kinase C-alpha (PKC-alpha) with small interference RNA (siRNA) agents. Asian Pac J Cancer Prev 13: 3631-3636. doi: 10.7314/APJCP.2012.13.8.3631 PMID: 23098446
29. Kuo MT (2009) Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 11: 99-133. doi: 10.1089/ars.2008.2095 PMID: 18699730
30. Shinoda C, Maruyama M, Fujishita T, Dohkan J, Oda H, et al. (2005) Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway. Int J Cancer 117: 21-31. doi: 10.1002/ijc.21094 PMID: 15880572
31. Yu ST, Chen TM, Tseng SY, Chen YH (2007) Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Commun 358: 79-84. doi: 10.1016/j.bbrc.2007. 04.107 PMID: 17482571
32. Saleh EM, El-Awady RA, Abdel Alim MA, Abdel Wahab AH (2009) Altered expression of proliferationinducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells. Cell Biochem Biophys 55: 95-105. doi: 10.1007/s12013-009-9058-3 PMID: 19593673
33. Yu ST, Chen TM, Chern JW, Tseng SY, Chen YH (2009) Downregulation of GSTpi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH2-terminal ki-nase-mediated apoptosis. Anticancer Drugs 20: 382-388. doi: 10.1097/CAD.0b013e32832a2cd4 PMID: 19318911
34. Safa AR, Pollok KE (2011) Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy. Cancers (Basel) 3: 1639-1671. doi: 10.3390/cancers3021639
35. Iseri OD, Kars MD, Arpaci F, Atalay C, Pak I, et al. (2011) Drug resistant MCF-7 cells exhibit epithelialmesenchymal transition gene expression pattern. Biomed Pharmacother 65: 40-45. doi: 10.1016/j. biopha.2010.10.004 PMID: 21177063
36. Shim GS, Manandhar S, Shin DH, Kim TH, Kwak MK (2009) Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med 47: 1619-1631. doi: 10.1016/j.freeradbiomed.2009.09.006 PMID: 19751820
37. Liu YY, Gupta V, Patwardhan GA, Bhinge K, Zhao Y, et al. (2010) Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer 9: 145. doi: 10.1186/1476-4598-9-145 PMID: 20540746
38. Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, et al. (2011) CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11: 418. doi: 10.1186/1471-2407-11-418 PMID: 21957977
39. Bourguignon LY, Xia W, Wong G (2009) Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and BclxL gene expression and chemoresistance in breast tumor cells. J Biol Chem 284: 2657-2671. doi: 10.1074/jbc.M806708200 PMID: 19047049
40. Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucette S, et al. (2009) The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 124: 806-815. doi: 10.1002/ijc.23987 PMID: 19035454
41. Nugoli M, Chuchana P, Vendrell J, Orsetti B, Ursule L, et al. (2003) Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. BMC Cancer 3: 13. doi: 10.1186/1471-2407-3-13 PMID: 12713671
42. Wang T, Arifoglu P, Ronai Z, Tew KD (2001) Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem 276: 20999-21003. doi: 10.1074/jbc.M101355200 PMID: 11279197
43. Furusawa S, Kimura E, Kisara S, Nakano S, Murata R, et al. (2001) Mechanism of resistance to oxidative stress in doxorubicin resistant cells. Biol Pharm Bull 24: 474-479. doi: 10.1248/bpb.24.474 PMID: 11379763
44. Bahr O, Wick W, Weller M (2001) Modulation of MDR/MRP by wild-type and mutant p53. J Clin Invest 107: 643-646. doi: 10.1172/JCI12415 PMID: 11238567
45. El-Deiry WS (2003) The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22: 7486-7495. doi: 10.1038/sj.onc.1206949 PMID: 14576853
46. Chen PL, Chen YM, Bookstein R, Lee WH (1990) Genetic mechanisms of tumor suppression by the human p53 gene. Science 250: 1576-1580. doi: 10.1126/science.2274789 PMID: 2274789
47. Maxwell SA, Roth JA (1994) Posttranslational regulation of p53 tumor suppressor protein function. Crit Rev Oncog 5: 23-57. doi: 10.1615/CritRevOncog.v5.i1.20 PMID: 7948107
48. Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JT, et al. (1995) Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ 6: 1395-1403. PMID: 8562478
49. Ogretmen B, Safa AR (1996) Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int J Cancer 67: 608-614. doi: 10.1002/ (SICI)1097-0215(19960904)67:5%3C608::AID-IJC3%3E3.0.CO;2-Y PMID: 8782646
50. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, et al. (1994) c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci U S A 91: 5878-5882. doi: 10.1073/pnas.91.13.5878 PMID: 8016082
51. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, et al. (1993) Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53: 4701-4714. PMID: 8402648
52. Kwak MK, Kensler TW (2010) Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244: 66-76. doi: 10.1016/j.taap.2009.08.028 PMID: 19732782
53. Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, et al. (2012) The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol 14: 715-720. doi: 10.1007/s12094-012-0866-3 PMID: 22911547
54. Subramaniam D, Ramalingam S, Houchen CW, Anant S (2010) Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev Med Chem 10: 359-371. doi: 10.2174/ 138955710791330954 PMID: 20370703
55. Hardt O, Wild S, Oerlecke I, Hofmann K, Luo S, et al. (2012) Highly sensitive profiling of CD44+/CD24-breast cancer stem cells by combining global mRNA amplification and next generation sequencing: evidence for a hyperactive PI3K pathway. Cancer Lett 325: 165-174. doi: 10.1016/j.canlet.2012.06.010 PMID: 22771536
56. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, et al. (2003) Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 102: 1466-1473. doi: 10.1182/blood-2003-02-0396 PMID: 12689934